Biogen

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Michel Vounatsos
CEOMichel Vounatsos
Employees
9,610
Employees9,610
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
9,610
Employees9,610

BIIB Key Statistics

Market cap
28.70B
Market cap28.70B
Price-Earnings ratio
13.98
Price-Earnings ratio13.98
Dividend yield
Dividend yield
Average volume
1.07M
Average volume1.07M
High today
$200.87
High today$200.87
Low today
$195.50
Low today$195.50
Open price
$197.50
Open price$197.50
Volume
849.02K
Volume849.02K
52 Week high
$291.54
52 Week high$291.54
52 Week low
$187.16
52 Week low$187.16

BIIB News

Reuters 45m
Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares - Reuters

A sign marks a Biogen facility, some of whose employees have tested positive for the coronavirus after attending a meeting in Boston, in Cambridge, Massachusett...

Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares - Reuters
MarketWatch 3h
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success - MarketWatch

Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late Tuesday lifted shares of Biogen Inc. BIIB, +1.04% to buy from neutr...

Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug success - MarketWatch
Benzinga 5h
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. BIIB and Eisai Co. Ltd. ESALY announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate. What Happe...

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Analyst ratings

55%

of 33 ratings
Buy
45.5%
Hold
54.5%
Sell
0%

BIIB Earnings

$0.00
$1.89
$3.79
$5.68
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Oct 19, Pre-Market
ActualExpected Oct 19, Pre-Market

More BIIB News

Investor's Business Daily 6h
Dow Jones Futures Fall On Apple iPhone Report, Rising Treasury Yields; Biogen Alzheimer's Drug Slows Decline | Investor's Business Daily - Investor's Business Daily

Dow Jones futures fell Wednesday morning, along with S&P 500 futures and Nasdaq futures. The 10-year Treasury yield moved right up the 4% level, while Apple (AA...

Dow Jones Futures Fall On Apple iPhone Report, Rising Treasury Yields; Biogen Alzheimer's Drug Slows Decline | Investor's Business Daily - Investor's Business Daily
Nikkei Asian Review 6h
Eisai-Biogen Alzheimer's drug slows spread by 'positive' 27% - Nikkei Asia

(Reuters) -- Eisai and Biogen on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of pati...

Eisai-Biogen Alzheimer's drug slows spread by 'positive' 27% - Nikkei Asia
Reuters 10h
UPDATE 1-Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline

(Adds expert reaction, share prices) By Deena Beasley and Julie Steenhuysen Sept 27 (Reuters) - An experimental Alzheimer's drug developed by Eisai Co Ltd and...

UPDATE 1-Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline
Reuters 10h
Factbox: Eisai-Biogen Alzheimer's drug success follows many failures - Reuters

Sept 27 (Reuters) - Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) reported late-stage data from their Alzheimer's disease drug lecanemab that show...

Factbox: Eisai-Biogen Alzheimer's drug success follows many failures - Reuters
NBC News 10h
Alzheimer's drug slowed progression of the disease in Phase 3 trial - NBC News

Japanese drugmaker Eisai on Tuesday said its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illn...

Alzheimer's drug slowed progression of the disease in Phase 3 trial - NBC News
Reuters 16h
Biden Medicare costs victory due mostly to Alzheimer's drug change - Reuters

Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providen...

Biden Medicare costs victory due mostly to Alzheimer's drug change - Reuters
Benzinga 24h
Biogen Settles For $900M In Bribe Case For Prescribing Multiple Sclerosis Drugs

Biogen Inc (NASDAQ: BIIB) has reached a $900 million settlement with a whistleblower who accused the firm of paying doctors bribes to encourage them to prescrib...

Biogen Settles For $900M In Bribe Case For Prescribing Multiple Sclerosis Drugs
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.